FDA Fully Approves AbbVie's Elahere For Ovarian Cancer
24/3 13:54
(RTTNews) - AbbVie (ABBV) said that the U.S. Food and Drug Administration has granted full approval for Elahere (mirvetuximab soravtansine-gynx) for the treatment of folate receptor alpha-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal adult...